Background: The therapeutic use of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to treat migraine has been understudied. Using three mouse models, we examined the impact of CBD and THC on migraine-relevant behaviors triggered by: 1) calcitonin gene-related peptide (CGRP), 2) sodium nitroprusside (SNP), and 3) cortical spreading depolarization (CSD). Methods: Both male and female CD1 mice were treated with CBD (100 mg/kg) or THC (1 mg/kg) alone or in combinations of CBD (1, 30 or 100 mg/kg) and THC (1 mg/kg) prior to injection of CGRP or SNP. The mice were assessed for light aversion (photophobia), squint (non-evoked pain), and periorbital tactile hypersensitivity, as well as possible adverse effects. In a separate set of experiments, CSD events were optogenetically induced in familial hemiplegic migraine 1 (FHM1) mutant and wildtype littermates (WT) mice (C57BL/6 background), followed by grimace and motor assessments with and without combinations of CBD (30 or 100 mg/kg) and THC (1 mg/kg). Results: In CD1 mice, a 100:1 CBD:THC combination mitigated light aversion induced by CGRP and SNP in males and females. Rescue of CGRP- and SNP-induced squint was observed only in male mice with 100:1 CBD:THC. None of the treatments rescued periorbital tactile hypersensitivity in either sex. In FHM1 mutant and WT mice, the 100:1 CBD:THC ratio did not affect CSD characteristics but did reduce CSD-induced grimace features (i.e., head pain mimic). No adverse effects of any of the cannabinoid treatments were observed using cognitive, emotional, or motor tests. Conclusions: A 100:1 ratio of CBD:THC has a beneficial effect on some of the most bothersome migraine-related symptoms in three mouse models. Our findings support a potential therapeutic efficacy of combined CBD and THC treatments.
Stroke can be followed by immediate severe headaches. As headaches are initiated by the activation of trigeminal meningeal afferents, we assessed changes in the activity of meningeal afferents in mice subjected to cortical photothrombosis. Cortical photothrombosis induced ipsilateral lesions of variable sizes that were associated with contralateral sensorimotor impairment. Nociceptive firing of mechanosensitive Piezo1 channels, activated by the agonist Yoda1, was increased in meningeal afferents in the ischemic hemispheres. These meningeal afferents also had a higher maximal spike frequency at baseline and during activation of the mechanosensitive Piezo1 channel by Yoda1. Moreover, in these meningeal afferents, nociceptive firing was active during the entire induction of transient receptor potential vanilloid 1 (TRPV1) channels by capsaicin. No such activation was observed on the contralateral hemi-skulls of the same group of mice or in control mice. Our data suggest the involvement of mechanosensitive Piezo1 channels capable of maintaining high-frequency spiking activity and of nociceptive TRPV1 channels in trigeminal headache pain responses after experimental ischemic stroke in mice.
Increasing endocannabinoids (endoCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), through inhibition of the degrading hydrolase enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively, has been proposed as approach to alleviate migraine pain. Notwithstanding, the impact of AEA and 2-AG on neuronal firing of meningeal afferents, which is relevant to the genesis of migraine pain, remains elusive. The impact of AEA and 2-AG on meningeal nerve afferent firing was examined through electrophysiological evaluation upon application of 50 mM KCl with or without DMSO, exogenous AEA (10 µM), or 2-AG (10 µM) to separate groups of C57BL/6J mouse hemiskull preparations. At the end of each experiment, capsaicin (1 µM), an agonist of TRPV1 channels, was tested, as a positive control of presumably nociceptive firing. Advanced clustering and spectral analysis on the electrophysiological data allowed differentiating spiking patterns with respect to their temporal and neurochemical profiles. Activity-based protein profiling and liquid chromatography with tandem mass spectrometry was used to assess endogenous FAAH and MAGL activity and determine endogenous levels of AEA and 2-AG in mouse meninges. Local application of endoCBs decreased KCl-induced firing of meningeal nerve afferents, which was most profound for AEA. AEA first produced a short, mild activation in firing, which was followed by a long-lasting reduction. Instead, 2-AG directly led to a short-lasting reduction in firing. Cluster analysis revealed that the transient activation by AEA involved fibers with small-amplitude spikes fired at rates of 1–2 Hz, whereas the persistently suppressed fibers consisted of high-amplitude spikes fired at rates exceeding 10 Hz. Only AEA inhibited subsequent capsaicininduced firing in the afferents long after AEA application, suggesting a broader mode of action for AEA than 2-AG. The more profound inhibitory effects of AEA are consistent with the observed higher activity of FAAH over MAGL and lower level of endogenous AEA than 2-AG in mouse meninges. Our study revealed a stronger anti-nociceptive action of AEA than of 2-AG, as measured by meningeal afferent firing in mouse hemiskulls. This difference can be exploited for relieving migraine pain by primarily increasing the tone of AEA through inhibition of FAAH outside the central nervous system.
Early stages of Alzheimer's disease are marked by brain hyperexcitability, evidenced by subclinical epileptiform features suggesting an excitation–inhibition imbalance. Clinically translatable biomarkers for early detection of excitation–inhibition changes at the network level, however, are lacking. We investigated the functional excitation–inhibition ratio, theta–gamma phase–amplitude coupling and epileptiform features in hippocampal and cortical local field potentials recorded weekly in freely behaving male APPswe/PS1dE9 (APP/PS1) mice (n = 10) and wild-type controls (n = 10) between 3 and up to and including 11 months of age. APP/PS1 mice exhibited a shift towards increased excitation, reflected in the elevated functional excitation–inhibition ratio emerging most prominently in the hippocampus at 6 months. Additionally, elevated population spiking activity and age-related impairments in theta–gamma phase–amplitude coupling were observed in the local field potentials of APP/PS1 mice in both the hippocampus and the cortex. Importantly, the functional excitation–inhibition ratio correlated positively with elevated population spiking activity in both brain regions in APP/PS1 mice. Our findings highlight the functional excitation–inhibition ratio as a promising biomarker of hippocampal and cortical network disinhibition and hyperexcitability in APP/PS1 mice, with potential value as an early disease marker in Alzheimer's disease.
Dravet syndrome (DS) is associated with epilepsy, developmental delays, thermal dysregulation, and sleep disturbances. While seizures have been linked to hippocampal dysfunction, what drives sleep disturbances and thermal dysregulation is poorly understood. Using DS mice ( Scn1aA1783V ), we identified a link between sleep and thermoregulation. We found that DS mice exhibited lower core body temperature. Next, using electrocorticography, local field potential recordings, and core temperature monitoring, we showed that DS mice exhibited a lack of core temperature change during the transition from waking to non-rapid eye movement sleep. This is in contrast to wild-type (WT) mice, in which sleep onset coincided with a temperature drop. Additionally, warmth promoted sleep in WT, but not in DS mice. Vector-mediated expression of SCN1A or chemogenetic stimulation of the anterior hypothalamus restored the warmth-induced somnogenesis in DS mice. These findings highlight a connection between sleep and thermal dysregulation in DS, implicating altered neuronal activity of the hypothalamus.